Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

2(29%)

Results Posted

33%(1 trials)

Phase Distribution

Ph phase_2

57%

Ph phase_4

29%

Ph phase_3

14%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 2Efficacy & side effects

4(57.1%)

Phase 3Large-scale testing

1(14.3%)

Phase 4Post-market surveillance

2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(3)

Other(1)

Detailed Status

Completed3

Not yet recruiting1

Recruiting1

unknown1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 24 (57.1%)

Phase 31 (14.3%)

Phase 42 (28.6%)

Trials by Status

not_yet_recruiting114%

completed343%

recruiting114%

unknown114%

active_not_recruiting114%

Recent Activity

2 active trials

Showing 5 of 7

completedphase_4

Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study

NCT04789174

active_not_recruitingphase_2

A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)

NCT06103825

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT04789174Phase 4

Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study

Completed

NCT06404099Phase 2

RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)

Active Not Recruiting

NCT06404086Phase 2

RECOVER-SLEEP: Platform Protocol

Completed

NCT06170970Phase 2

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

Recruiting

NCT06103825Phase 3

A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)

Completed

NCT06590662Phase 2

Efficacy and Tolerance of Solriamfetol in Patients Affected with Idiopathic Hypersomnia.

Not Yet Recruiting

NCT04602936Phase 4

Solriamfetol in Binge Eating Disorder

Unknown

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7